AG-920

DRUG5 trials

Sponsors

American Genomics, LLC

Conditions

Anesthesia, LocalHealthy

Phase 1

An Open Label, Study of the Systemic Exposure to Articaine After Topical Ocular Dosing of AG-920

CompletedNCT04759339

American Genomics, LLCHealthy

Start: 2021-02-24End: 2021-02-25Updated: 2022-04-29

Phase 3

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

CompletedNCT04513652

American Genomics, LLCAnesthesia, Local

Start: 2020-09-03End: 2020-12-17Updated: 2022-09-28

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

CompletedNCT04829344

American Genomics, LLCAnesthesia, Local

Start: 2021-03-30End: 2021-05-10Updated: 2024-10-10

A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population

CompletedNCT05325853

American Genomics, LLCAnesthesia, Local

Start: 2022-04-06End: 2022-05-27Updated: 2023-10-25

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

CompletedNCT05501860

American Genomics, LLCAnesthesia, Local

Start: 2022-07-30End: 2022-12-07Updated: 2024-10-09

Related Papers

Two Randomized, Double-masked, Placebo-controlled Studies of the Local Anesthetic Effect of Articaine Ophthalmic Solution

Clinical ophthalmology2023-05-012 citations

Early Nonclinical and Clinical Development of AG-920, a Repurposed Topical Ocular Anesthetic

Journal of Ocular Pharmacology and Therapeutics2022-07-192 citations